Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.04 USD | +3.78% | +0.63% | -27.39% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.39% | 1.48B | |
-19.68% | 10.82B | |
+47.54% | 3.25B | |
-33.46% | 2.11B | |
-17.21% | 2.08B | |
+20.61% | 1.02B | |
-4.37% | 733M | |
-34.67% | 391M | |
-45.51% | 383M | |
+13.32% | 332M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook